QazCovid-in
Vaccine candidate against COVID-19
From Wikipedia, the free encyclopedia
QazCovid-in, commercially known as QazVac,[1][2] is a COVID-19 vaccine developed by the Research Institute for Biological Safety Problems in Kazakhstan.[3][4] QazCoVac-P was the second COVID-19 vaccine developed by the Kazakh Biosafety Research Institute and in clinical trials.[5]
- 2541708-50-1
- QazCoVac-P: 2699021-46-8
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Inactivated |
| Clinical data | |
| Routes of administration | Intramuscular |
| Identifiers | |
| CAS Number |
|
| DrugBank | |
Manufacturing
The vaccine can be stored at standard refrigeration temperatures (2 °C-8 °C) and is a two-dose régime with the doses administered twenty-one days apart.[6] The vaccine was first manufactured by Kazakhstan's Research Institute of Biological Safety Problems. Production capacity was capped at 50,000 doses per month.[citation needed]
The vaccine was slated to be packaged in bulk and be bottled in Turkey by a Turkish company beginning in June 2021.[7] It was intended for a production capacity of 500,000-600,000 doses per month.[8] The contract was still being negotiated as of April 2021,[9] despite earlier claims suggesting that the deal had already been finalized.[10][11]
In October 2021, it was announced that the vaccine would be supplied to Afghanistan and other countries in 2022.[12]
History
Clinical trials
In September 2020, QazVac started in Phase I/II clinical trials.[13]
In December 2020, QazVac was in Phase III clinical trials, which was expected to be fully completed by 9 July 2021.[2][7] It is unclear when the first preliminary results will be published.[14][11]
The administration of the vaccine for the general population began at the end of April 2021.[15] The Research Institute Kunsulu Zakarya's Director General's justification is that the trial is almost 50% completed and "people who have received [the] vaccine feel well; there have been no side-effects and the effectiveness of the vaccine is high".[7]
In September 2021, a study was published to eClinicalMedicine, published by The Lancet. The study’s findings were that the "QazCovid-in® vaccine was safe and well-tolerated and induced predominantly mild adverse events; no serious or severe adverse events were recorded in both trials." [16]
Authorization
Economics
The first batch of 50,000 doses was delivered on 26 April 2021, and vaccination began shortly after.[citation needed] In June 2021, the capacity was intended increase to 100,000 doses per month, regardless of the contract for bottling in Turkey.[17]
.svg){kind=small}